RT @IoanaA_Cristea: @EikoFried Patient advocacy also appears to have significantly contributed to some of the most questionable FDA approva…
RT @IoanaA_Cristea: @EikoFried Patient advocacy also appears to have significantly contributed to some of the most questionable FDA approva…
@EikoFried Patient advocacy also appears to have significantly contributed to some of the most questionable FDA approvals, such as https://t.co/qpgKOdqSjg https://t.co/Gitl4IadqY
... or eteplirsen for muscular dystrophy (by FDA) despite a lack of clinical evidence... https://t.co/55yTpB5VMd
@adamfeuerstein @akesselheim @nytimes Aaron's been pretty clear on this one: https://t.co/BSuOyx5F49 I'm more curious about the flipside. Which are the best uses of AA? I mean, we can all agree on Gleevec...
In 2016 eteplirsen won a stunning and controversial approval, "overruling the recommendations of both its scientific staff and its external advisory committee." https://t.co/SZjk3KDQHs
RT @JonathanDarrow: Even where drugs do not "fail," efficacy can be so low that their approval is still a failure for patients. E.g. etep…
RT @JonathanDarrow: Even where drugs do not "fail," efficacy can be so low that their approval is still a failure for patients. E.g. etep…
RT @VPrasadMDMPH: Loss of standards have been intensifying with approvals like: Exondys 51 - ooff https://t.co/SjPqKcwvg3
RT @VPrasadMDMPH: Loss of standards have been intensifying with approvals like: Exondys 51 - ooff https://t.co/SjPqKcwvg3
Loss of standards have been intensifying with approvals like: Exondys 51 - ooff https://t.co/SjPqKcwvg3
RT @JAMA_current: Implications of the FDA Approval of #Eteplirsen for #MuscularDystrophy https://t.co/jZqK18GyHa
RT @JAMA_current: Implications of the FDA Approval of #Eteplirsen for #MuscularDystrophy https://t.co/9HCAJa8SmW
RT @JAMA_current: Implications of the FDA Approval of #Eteplirsen for #MuscularDystrophy https://t.co/9HCAJa8SmW
Myopathie de Duchenne : l'homologation problématique de l'eteplirsen par la @US_FDA https://t.co/VBGB8WsYaf see more https://t.co/LKKwSW7zkh
RT @JAMA_current: Implications of the FDA Approval of #Eteplirsen for #MuscularDystrophy https://t.co/9HCAJa8SmW
RT @JAMANeuro: Implications of the FDA Approval of #Eteplirsen for #MuscularDystrophy https://t.co/LhvQCeKmjs
RT @JAMA_current: Implications of the FDA Approval of #Eteplirsen for #MuscularDystrophy https://t.co/9HCAJa8SmW
RT @JAMA_current: For now, #eteplirsen has provided a worrisome model for the next generation of molecularly targeted therapies https://t.c…
Implications of the FDA Approval of #Eteplirsen for #MuscularDystrophy https://t.co/9HCAJa8SmW
Implications of the FDA Approval of #Eteplirsen for #MuscularDystrophy https://t.co/qM6nuJkWr2
Implications of the FDA Approval of #Eteplirsen for #MuscularDystrophy https://t.co/LhvQCeKmjs
RT @JAMA_current: For now, #eteplirsen has provided a worrisome model for the next generation of molecularly targeted therapies https://t.c…
RT @JAMA_current: For now, #eteplirsen has provided a worrisome model for the next generation of molecularly targeted therapies https://t.c…
For now, #eteplirsen has provided a worrisome model for the next generation of molecularly targeted therapies https://t.co/oihHNiUrpX
"Implications of the #FDA Approval of Eteplirsen for Muscular Dystrophy" https://t.co/cjInW0oNJm
Approving a Problematic Muscular Dystrophy Drug: Implications for FDA Policy https://t.co/uw2jIbITuH #Duchenne
Implications of the FDA Approval of Eteplirsen for Muscular Dystrophy https://t.co/jcHTcbBPXh
Implications of the FDA Approval of Eteplirsen for Muscular Dystrophy https://t.co/zexm2kVHFF
Implications of the FDA Approval of Eteplirsen for Muscular Dystrophy https://t.co/tUkerIYfZT
Ilustración sobre el Signo de Gowers en la Distrofia Muscular de Duchenne https://t.co/D7u4JqKXWD
Implications of the FDA Approval of Eteplirsen for Muscular Dystrophy https://t.co/mFWkCvy4Jf
penalizes manufacturers that pursue a more rigorous course of development using more clinically relevant end points. https://t.co/d5fsG31YeA
Very interesting issue! RT Implications of the FDA Approval of Eteplirsen for Muscular Dystrophy https://t.co/xqf9bQsOnQ
RT @kyleserikawa: Implications of the @US_FDA Approval of #Eteplirsen for #MuscularDystrophy https://t.co/4mFnZ9quXU by @akesselheim in @JA…
A must read for anyone interested in #orphan disease or #drug approval. #DMD #eteplirsen #oligos https://t.co/HRus4YR4AD
Implications of the FDA Approval of Eteplirsen for Muscular Dystrophy https://t.co/pRGlRdu5Ab
RT @yemj111: من صفحة الـ" أ . د . أمين الكمالي / استشاري جراحة المخ والأعصاب والعمود الفقري... https://t.co/jyNfc51BHD
RT @yemj111: من صفحة الـ" أ . د . أمين الكمالي / استشاري جراحة المخ والأعصاب والعمود الفقري... https://t.co/jyNfc51BHD
من صفحة الـ" أ . د . أمين الكمالي / استشاري جراحة المخ والأعصاب والعمود الفقري... https://t.co/jyNfc51BHD
Alumnus @akesselheim co-published the study, "Approving a Problematic Muscular Dystrophy Drug" on @JAMA_current https://t.co/68ihwhZvRK
Approving a Problematic Muscular Dystrophy Drug: Implications of the FDA Approval of Eteplirsen for DMD https://t.co/kNz2kn66Ri
RT @JAMAPeds: Implications of the @US_FDA Approval of #Eteplirsen for #MuscularDystrophy https://t.co/pFrc43ZXRW https://t.co/I3IET20n4c
Some of the unfortunate consequences of the Sarepta approval process https://t.co/aNAJwbTrDu
"@JAMA_current: Implications of the @US_FDA Approval of #Eteplirsen for #MuscularDystrophy https://t.co/LTStKdrBzF https://t.co/oRZosVXN6T
"@JAMA_current: Implications of the @US_FDA Approval of #Eteplirsen for #MuscularDystrophy https://t.co/LTStKdrBzF https://t.co/oRZosVXN6T
RT @JAMA_current: Implications of the @US_FDA Approval of #Eteplirsen for #MuscularDystrophy https://t.co/yCHM8kjZIT https://t.co/FFzgSrmjPe
RT @onceuponA: The troubling implications that emerge from FDA's controversial approval of Sarepta's muscular dystrophy drug: https://t.co/…
On #eteplirsen approval: “Speeding drugs to market based on biomarker outcomes can actually lead to a worse outcome” https://t.co/NYDHm2RI5P
RT @healthcarebiz: Implications of the FDA Approval of #Eteplirsen for Muscular Dystrophy https://t.co/yrhjxNzW0a #FDA via @JAMA_current
Implications of the FDA Approval of #Eteplirsen for Muscular Dystrophy https://t.co/yrhjxNzW0a #FDA via @JAMA_current
A brilliant piece on Eteplirsen by Kesselheim and Avorn! The last sentence is extremely insighful, and scary https://t.co/5OCOV4ZRlL
RT @nicholas_bagley: This from @akesselheim and Jerry Avorn is just devastating on FDA's approval of eteplirsen: https://t.co/ylP088prYU
RT @JAMA_current: Implications of the @US_FDA Approval of #Eteplirsen for #MuscularDystrophy https://t.co/yCHM8kjZIT https://t.co/FFzgSrmjPe
RT @JAMA_current: Implications of the @US_FDA Approval of #Eteplirsen for #MuscularDystrophy https://t.co/yCHM8kjZIT https://t.co/FFzgSrmjPe
RT @nicholas_bagley: This from @akesselheim and Jerry Avorn is just devastating on FDA's approval of eteplirsen: https://t.co/ylP088prYU
RT @JAMAPeds: Implications of the @US_FDA Approval of #Eteplirsen for #MuscularDystrophy https://t.co/pFrc43ZXRW https://t.co/I3IET20n4c
Plébiscite / assos patts ms t décourgt pr les Pharmas qui essaient enc de fr un travail correct, c le dit J Avorn https://t.co/1nMVz2gVea
RT @PORTAL_Research: @PORTAL_Research JAMA Commentary $SRPT #Eteplirsen @JAMA_current: https://t.co/dtf0xBLfdL @Forbes @John_LaMattina: ht…
RT @JAMA_current: #Eteplirsen has provided a worrisome model for the next generation of molecularly targeted therapies https://t.co/jH7QHRP…
Implications of the FDA Approval of Eteplirsen for Muscular Dystrophy https://t.co/7CTWF6HHkc
RT @lucadf: Speeding drugs to market based on such biomarker outcomes can actually lead to a worse outcome for patients. https://t.co/gL9dP…
RT @lucadf: Speeding drugs to market based on such biomarker outcomes can actually lead to a worse outcome for patients. https://t.co/gL9dP…
RT @lucadf: Speeding drugs to market based on such biomarker outcomes can actually lead to a worse outcome for patients. https://t.co/gL9dP…
RT @hastingscenter: #Duchenne decision is defensible, Hastings Center president says, IF there's FDA follow-through https://t.co/04XTMdEuoP…
JAMA: Implications of FDA Approval of Eteplirsen for Muscular Dystrophy https://t.co/QFJWRGMeoY. See my analysis: https://t.co/Xh2pCBRqHy.
Speeding drugs to market based on such biomarker outcomes can actually lead to a worse outcome for patients. https://t.co/gL9dPMWLb8 https://t.co/QprBYWxpNZ
#Duchenne decision is defensible, Hastings Center president says, IF there's FDA follow-through https://t.co/04XTMdEuoP https://t.co/geFKphhtcH
Approving a problematic Muscular Dystrophy Drug #DMD #MD #FDA #Sarepta - Implications for FDA Policy https://t.co/WsJugg2dLg
Bad day for drug regulation and (probably) for @CoalitionDMD Dubious & risky FDA approval of eteplirsen for Duchenne https://t.co/3KyUtpKyzG
RT @JAMANeuro: Implications of the @US_FDA Approval of #Eteplirsen for #MuscularDystrophy https://t.co/eSHEnknuuS https://t.co/XJz1YFb2wu
RT @JAMA_current: Implications of the @US_FDA Approval of #Eteplirsen for #MuscularDystrophy https://t.co/yCHM8kjZIT https://t.co/FFzgSrmjPe
RT @JAMAPeds: Implications of the @US_FDA Approval of #Eteplirsen for #MuscularDystrophy https://t.co/pFrc43ZXRW https://t.co/I3IET20n4c
Important pts on FDA approval concerns re: eteplirsen by @akesselheim. Suggestions for faster but safe FDA approval? https://t.co/EfXKcpFwwU
Implications of the FDA Approval of Eteplirsen for Muscular Dystrophy https://t.co/qPdwgQ0wFv
Implications of the FDA Approval of Eteplirsen for Muscular Dystrophy. Is the FDA Too Compliant? https://t.co/ErjHaetmKF
Troublesome Implications of @US_FDA Approval of Eteplirsen for Muscular Dystrophy via @JAMANetwork & @akesselheim https://t.co/fVN4AQKL0o
RT @JAMAPeds: Implications of the @US_FDA Approval of #Eteplirsen for #MuscularDystrophy https://t.co/pFrc43ZXRW https://t.co/I3IET20n4c
En JAMA: Implications of the FDA Approval of Eteplirsen for Muscular Dystrophy https://t.co/yfxpdCT793
RT @matthewherper: $srpt https://t.co/pIJQ3eg3Tv
$SRPT Implications of the FDA Approval of Eteplirsen for Muscular Dystrophy | Neurology | JAMA | The JAMA Network https://t.co/XIwsfnmOhw
RT @ontargt: Implications of the FDA Approval of Eteplirsen for Muscular Dystrophy $srpt https://t.co/42zBgDOX3K
RT @JAMA_current: Implications of the @US_FDA Approval of #Eteplirsen for #MuscularDystrophy https://t.co/yCHM8kjZIT https://t.co/FFzgSrmjPe
$SRPT Implications of the FDA Approval of Eteplirsen for Muscular Dystrophy https://t.co/cWrZKNOHUT
RT @nicholas_bagley: This from @akesselheim and Jerry Avorn is just devastating on FDA's approval of eteplirsen: https://t.co/ylP088prYU
RT @LeoUzych: Implications of the #FDA Approval of #Eteplirsen for #MuscularDystrophy https://t.co/Ka5ECiaIb2
@US_FDA OK of #DMD Rx= a worrisome model 4 Next-gen molecularly-targt therapies @akesselheim & Avorn https://t.co/wwzoBpGeGT
Implications of the #FDA Approval of #Eteplirsen for #MuscularDystrophy https://t.co/Ka5ECiaIb2
Implications of the FDA Approval of Eteplirsen for Muscular Dystrophy https://t.co/1BCyYNrYZv
Implications of the FDA Approval of Eteplirsen for Muscular Dystrophy https://t.co/npr6TbQbTO
Approving a Problematic Muscular Dystrophy Drug - Implications for FDA Policy https://t.co/8OE9ToNFMG
RT @nicholas_bagley: This from @akesselheim and Jerry Avorn is just devastating on FDA's approval of eteplirsen: https://t.co/ylP088prYU
Implications of the FDA Approval of Eteplirsen for Muscular Dystrophy $srpt https://t.co/42zBgDOX3K
RT @JAMA_current: #Eteplirsen has provided a worrisome model for the next generation of molecularly targeted therapies https://t.co/jH7QHRP…
Implications of the FDA Approval of Eteplirsen for Muscular Dystrophy | Neurology | JAMA | The JAMA Network https://t.co/zClRBempny
"This approach..unfairly penalizes manufacturers that pursue a more rigorous course of development using more clinically relevant endpoints" https://t.co/mq9yFf4b3V
Troublesome Implications of @US_FDA Approval of Eteplirsen for Muscular Dystrophy via @JAMANetwork & @akesselheim https://t.co/fVN4AQKL0o
Implications of the FDA Approval of Eteplirsen for Muscular Dystrophy https://t.co/9ZsrNoFlAj
Implications of the FDA Approval of Eteplirsen for Muscular Dystrophy https://t.co/Kk2cI8p2nL